Discover our pipeline and understand how our targeted approaches are being developed.
Driving discovery through the unique exploitation of cross-discipline expertise in drug development
Sitryx is building a broad and differentiated pipeline by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.
|SIT-052SEN||Idiopathic pulmonary fibrosis|
|SIT-033KIN||Inflammatory bowel disease|
|SIT-022MLE||Inflammatory bowel disease|
|SIT-047OCM||Systemic lupus erythematosus|
Intervening in cell metabolism, to reverse and resolve inflammation and tissue damage, leading to better outcomes.
Offering the potential for a broader population of patients to achieve remission in a range of severe diseases in immunology and oncology.